Drug major Sun Pharmaceutical Industries Ltd. has received a partial relief from a U.S. court in a litigation alleging delay by the company in launching three generic drugs in the American market.
The Mumbai-based company is a defendant in a multi-district litigation brought by various classes of plaintiffs in the U.S. District Court (District of Massachusetts), alleging a delay in the market entry for three generic drugs -- Valganciclovir, Valsartan and Esomeprazole.
-
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI -
"I Am A Material Man In A Material World': Quantum Advisors' Ajit Dayal On NDTV Profit Ignite
The complaints assert claims under the Racketeer Influenced and Corrupt Organizations Act, federal and state antitrust laws, and state consumer protection laws, Sun Pharma said in a regulatory filing.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
"On Nov. 27, 2019, the U.S. District Court (District of Massachusetts) entered a decision denying in part and granting in part Sun Pharma's motion to dismiss the claims of certain plaintiffs," it said.
"Under the ruling the majority of those plaintiff's claims survive and several state law claims are dismissed," it added.
The company said it would continue to vigorously defend against all claims and is also considering its appeal options as to the claims that were not dismissed in the above court decision.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
